aHUS care pathway
The care pathway for aHUS patients has been looked at in detail in Global Action’s Diagnosis Process Study ( for reports…
aHUS limitations
Zinovieva asked two related questions in the RDD 2020 video The issues of what provokes ( or triggers) the development of…
aHUS remission chance and relapse risk
Remission from aHUS is different from having been cured because there is still an uncertainty that aHUS can return. If that…
COVID TRIGGERS aHUS
It was March 2020 and COVID appears on www.ahusallianceaction.org for first time with a question: Can the coronavirus trigger an infection…
YOU’VE GOT aHUS!
The third article in the series about the aHUS Diagnosis Process is published today. Rare Disease Day 2022 The article covers…
aHUS Diagnosis Process – Report 2
The second article in the series about the aHUS Diagnosis Process has been published on the website today. Research made possible…
aHUS Trial Watch 14
A trial has been designed by Alexion to examine the efficacy of Ravulizumab to treat those with a Thrombotic Microngiopathy ,…
One genetic problem but two diseases
Take "diacylglycerol kinase " and add a "syndrome" throw in a letter from the Greek alphabet " ε" and you have…
TMA-Semantics are important
Article No. 402 12 December 2020 Just over a year ago aHUS Global Action featured a series of articles "aHUS is…
- Go to the previous page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- Go to the next page